Table 1 Patient characteristics
From: Radiotherapy-induced toxicity in prostate cancer patients with hip prostheses
Group with bilateral hip prostheses | Control group | |
|---|---|---|
Sample size | 17 | 50 |
Median age (years), range | 77, 65–84 | 77, 64–83 |
T stage: ≤ T1c | 2 (12%) | 3 (6%) |
T2a–T2c | 7 (41%) | 43 (86%) |
≥ T3a | 8 (47%) | 4 (8%) |
Androgen deprivation therapy | ||
None | 2 (12%) | 6 (12%) |
< 6 months | 1 (6%) | 1 (2%) |
6–12 months | 4 (24%) | 43 (86%) |
> 12 months | 10 (59%) | 0 (0%) |
Radiotherapy prescription | ||
57 Gy in 19 fractions | 3 (18%) | 8 (16%) |
60 Gy in 20 fractions | 14 (82%) | 42 (84%) |
Median CTV volume (cc), range | 56.3, 21.8–144.1 | 47.1, 22.1–135.9 |
Bladder filling: empty | 14 (82%) | 39 (78%) |
full | 3 (18%) | 11 (22%) |
Median hip separation (cm), range | 13.5 (11.2, 16.2) | 12.8 (10.8,14.5) |